PREVIEW

Eli Lilly Issues Warning About Fake Weight-Loss Drugs. On June 20, Eli Lilly published an open letter, warning about fake and compounded versions of Mounjaro and Zepbound, ABC News reports. "Lilly is committed to making life better for people living with diabetes and obesity through developing medicines that change the way healthcare providers can treat these diseases." "Lilly Stands Against the Use of its Medicines for Cosmetic Weight Loss." The company went on to advise consumers to stay away from buying weight-loss drugs online without a prescription. "Lilly is deeply concerned about the proliferation of online sales and posts on social media involving counterfeit, fake, compounded, and any other unsafe or untested versions of what they say is tirzepatide." "Any products marketed simply as “tirzepatide” (as opposed to Mounjaro® and Zepbound®) were not made by, studied by, or sold by Lilly and are not FDA-approved." "Be aware that when you purchase products that are not FDA-approved medicines or obtain medicines from an unverified source or without a prescription from a licensed healthcare provider, you may be purchasing fake, counterfeit, or otherwise unsafe products." , Eli Lilly, via open letter. Eli Lilly also addressed concerns about compounded medications. Although compounding is legal amid drug shortages, the FDA has shared concerns about substandard products. Eli Lilly says that it has tested some compounded versions of its products, only to find safety and efficacy issues. Some products had high bacteria counts and impurities, while others were entirely different chemical structures. THIS VIDEO MUST NOT BE EDITED FOR LENGTH TO COMBINE WITH OTHER CONTENT